Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Clinical Research in Cardiology
Erschienen in: Clinical Research in Cardiology 4/2011

01.04.2011 | Original Paper

Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure

verfasst von: Michael Behnes, Ursula Hoffmann, Siegfried Lang, Christel Weiss, Parviz Ahmad-Nejad, Michael Neumaier, Martin Borggrefe, Martina Brueckmann

Erschienen in: Clinical Research in Cardiology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Atrial fibrillation (AF) and acute congestive heart failure (aCHF) are characterized by an adverse cardiac remodeling. Arrhythmogenic or structural remodeling can be caused by interstitial fibrosis. Transforming growth factor beta 1 (TGF-beta 1) represents a central regulator of cardiac fibrosis. This study investigates serum levels of TGF-beta 1 in patients with AF and aCHF.

Methods

401 patients presenting with symptoms of dyspnea or peripheral edema were prospectively enrolled. Blood samples for measurement of TGF-beta 1 (R&D Systems, Inc.) and amino-terminal pro-brain natriuretic peptide (NT-proBNP) (DadeBehring ltd.) were collected after the initial clinical evaluation.

Results

Median TGF-beta 1 levels were lower in patients with AF (21.0 ng/ml, interquartile range (IR) 15.4–27.6 ng/ml, n = 107) compared to those without (25.0 ng/ml, IR 18.5–31.6 ng/ml, n = 294) (p = 0.009). Patients with aCHF had lower TGF-beta 1 levels (median 22.0 ng/ml, IR 15.6–27.1 ng/ml, n = 122) than those without (median 24.9 ng/ml, IR 18.1–31.9 ng/ml, n = 279) (p = 0.0005). In logistic regression models TGF-beta 1 was still associated with AF (odds ratio (OR) 3.00, 95% CI 1.37–6.61, p = 0.0001) and aCHF (OR 3.98, 95% CI 1.55–10.19, p = 0.004). TGF-beta 1 inversely correlated with left atrial diameter (r = −0.30, p = 0.007) and NT-proBNP (r = −0.14, p = 0.007).

Conclusions

Low serum levels of TGF-beta 1 are associated with AF and aCHF. This decrease may result from a higher consumption of TGF-beta 1 within the impaired myocardium or antifibrotic functions of natriuretic peptides.
Literatur
1.
Kirchhof P, Bax J, Blomstrom-Lundquist C et al (2009) Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled ‘research perspectives in atrial fibrillation’. Europace 11:860–885PubMedCrossRef
2.
Horlitz M, Schley P, Shin DI et al (2008) Atrial tachycardias following circumferential pulmonary vein ablation: observations during catheter ablation. Clin Res Cardiol 97:124–130PubMedCrossRef
3.
Nitardy A, Langreck H, Dietz R et al (2009) Reduction of right ventricular pacing in patients with sinus node dysfunction through programming a long atrioventricular delay along with the DDIR mode. Clin Res Cardiol 98:25–32PubMedCrossRef
4.
Hauck M, Bauer A, Voss F et al (2009) Effect of cardiac resynchronization therapy on conversion of persistent atrial fibrillation to sinus rhythm. Clin Res Cardiol 98:189–194PubMedCrossRef
5.
Tebbe U, Oeckinghaus R, Appel KF et al (2008) AFFECT: a prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation. Clin Res Cardiol 97:389–396PubMedCrossRef
6.
Watson T, Shantsila E, Lip GY (2009) Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 373:155–166PubMedCrossRef
7.
Opie LH, Commerford PJ, Gersh BJ et al (2006) Controversies in ventricular remodelling. Lancet 367:356–367PubMedCrossRef
8.
Dickstein K, Cohen-Solal A, Filippatos G et al (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29:2388–2442
9.
Dagli N, Karaca I, Yavuzkir M et al (2008) Are maximum P wave duration and P wave dispersion a marker of target organ damage in the hypertensive population? Clin Res Cardiol 97:98–104PubMedCrossRef
10.
Plisiene J, Blumberg A, Haager G et al (2008) Moderate physical exercise: a simplified approach for ventricular rate control in older patients with atrial fibrillation. Clin Res Cardiol 97:820–826PubMedCrossRef
11.
Towbin JA (2007) Scarring in the heart—a reversible phenomenon? N Engl J Med 357:1767–1768PubMedCrossRef
12.
Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342:1350–1358PubMedCrossRef
13.
Akinci B, Bayraktar F, Saklamaz A et al (2007) Low transforming growth factor-beta1 serum levels in idiopathic male osteoporosis. J Endocrinol Invest 30:350–355PubMed
14.
Stefoni S, Cianciolo G, Donati G et al (2002) Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 61:324–335PubMedCrossRef
15.
Gordon KJ, Blobe GC (2008) Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta 1782:197–228PubMed
16.
Khan R, Sheppard R (2006) Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 118:10–24PubMedCrossRef
17.
Clarke DC, Liu X (2008) Decoding the quantitative nature of TGF-beta/Smad signaling. Trends Cell Biol 18:430–442PubMedCrossRef
18.
Weber KT (1997) Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 96:4065–4082PubMed
19.
Behnes M, Brueckmann M, Ahmad-Nejad P et al (2009) Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema. Int J Cardiol 135:165–174PubMedCrossRef
20.
Behnes M, Lang S, Breithardt OA et al (2008) Association of NT-proBNP with severity of heart valve disease in a medical patient population presenting with acute dyspnea or peripheral edema. J Heart Valve Dis 17:557–565PubMed
21.
Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–2429
22.
Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839–843PubMed
23.
Corda S, Samuel JL, Rappaport L (2000) Extracellular matrix and growth factors during heart growth. Heart Fail Rev 5:119–130PubMedCrossRef
24.
Leask A (2007) TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res 74:207–212PubMedCrossRef
25.
Zeisberg EM, Tarnavski O, Zeisberg M et al (2007) Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13:952–961PubMedCrossRef
26.
Xiao H, Zhang YY (2008) Understanding the role of transforming growth factor-beta signalling in the heart: overview of studies using genetic mouse models. Clin Exp Pharmacol Physiol 35:335–341PubMedCrossRef
27.
Everett THt, Olgin JE (2007) Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 4:S24–S27PubMedCrossRef
28.
Li X, Ma C, Dong J et al (2008) The fibrosis and atrial fibrillation: is the transforming growth factor-beta(1) a candidate etiology of atrial fibrillation. Med Hypotheses 70:317–319PubMedCrossRef
29.
Lim H, Zhu YZ (2006) Role of transforming growth factor-beta in the progression of heart failure. Cell Mol Life Sci 63:2584–2596PubMedCrossRef
30.
MacLellan WR (2000) Advances in the molecular mechanisms of heart failure. Curr Opin Cardiol 15:128–135PubMedCrossRef
31.
Xu J, Cui G, Esmailian F et al (2004) Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 109:363–368PubMedCrossRef
32.
Lin CS, Pan CH (2008) Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci 65:1489–1508PubMedCrossRef
33.
Du J, Xie J, Zhang Z et al (2010) TRPM7-mediated Ca2+ signals confer fibrogenesis in human atrial fibrillation. Circ Res 106:992–1003
34.
Nishikimi T, Maeda N, Matsuoka H (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69:318–328PubMedCrossRef
35.
Ogawa Y, Tamura N, Chusho H et al (2001) Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. Can J Physiol Pharmacol 79:723–729PubMedCrossRef
36.
Letsas KP, Filippatos GS, Pappas LK et al (2009) Determinants of plasma NT-pro-BNP levels in patients with atrial fibrillation and preserved left ventricular ejection fraction. Clin Res Cardiol 98:101–106PubMedCrossRef
37.
Li P, Wang D, Lucas J et al (2008) Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res 102:185–192PubMedCrossRef
38.
39.
Dobrev D (2010) Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target. Naunyn Schmiedebergs Arch Pharmacol 381:195–206PubMedCrossRef
40.
Dobrev D,Nattel S (2008) Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J Cardiovasc Pharmacol 52:293–299PubMedCrossRef
Metadaten
Titel
Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure
verfasst von
Michael Behnes
Ursula Hoffmann
Siegfried Lang
Christel Weiss
Parviz Ahmad-Nejad
Michael Neumaier
Martin Borggrefe
Martina Brueckmann
Publikationsdatum
01.04.2011
Verlag
Springer-Verlag
Erschienen in
Clinical Research in Cardiology / Ausgabe 4/2011
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-010-0248-1

Weitere Artikel der Ausgabe 4/2011

Clinical Research in Cardiology 4/2011 Zur Ausgabe

Original Paper

Effects of intracoronary injection of autologous bone marrow-derived stem cells on natriuretic peptides and inflammatory markers in patients with acute ST-elevation myocardial infarction

Original Paper

Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease

Laudatio

In honor of Professor Dr. med. Gerhard Riecker on his 85th birthday

Original Paper

Right ventricular function in grown-up patients after correction of congenital right heart disease

Original Paper

Impact of minimising door-to-balloon times in ST-elevation myocardial infarction to less than 30 min on outcome: an analysis over an 8-year period in a tertiary care centre

Original Paper

Prognostic value of electrocardiographic detection of unrecognized myocardial infarction in persons with stable coronary artery disease: data from the Heart and Soul Study

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen